Mitigating radiation-induced toxicity: an overview of new approaches developed at the French Military Biomedical Research Institute.
Acute radiation syndrome represents the clinical response of radiation-sensitive key tissues (i.e., hematopoietic, gastrointestinal and neurovascular) following exposure to high doses of ionizing radiation. In this context, the hematopoietic syndrome remains the first therapeutic challenge. Today, identifying new drugs and developing new strategies to cope with acute radiation syndrome remain a priority, especially to prevent/cure the radiation-induced multiple organ dysfunction syndrome then failure. Cytokine, non-cytokine drugs, and cell/gene therapy represent a pattern of sophisticated approaches developed by this group and others to achieve this goal.
*Institut de Recherche Biomédicale des Armées, Department of Radiobiology, BP73, 91223, Brétigny sur Orge, France.
Michel
M
Drouet
Francis
F
Hérodin
D000047:Academies and Institutes; D054508:Acute Radiation Syndrome / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D016207:Cytokines / Q000494:pharmacology / Q000627:therapeutic use; D020868:Gene Silencing; D015316:Genetic Therapy; D006801:Humans
D016207:Cytokines